194 related articles for article (PubMed ID: 29275295)
21. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).
Zhou Q; Chen J; Feng J; Wang J
Tumour Biol; 2016 Mar; 37(3):3105-13. PubMed ID: 26427660
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
24. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
25. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
[TBL] [Abstract][Full Text] [Related]
26. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
[TBL] [Abstract][Full Text] [Related]
27. Increased Global DNA Hypomethylation in Distant Metastatic and Dedifferentiated Thyroid Cancer.
Klein Hesselink EN; Zafon C; Villalmanzo N; Iglesias C; van Hemel BM; Klein Hesselink MS; Montero-Conde C; Buj R; Mauricio D; Peinado MA; Puig-Domingo M; Riesco-Eizaguirre G; Reverter JL; Robledo M; Links TP; Jordà M
J Clin Endocrinol Metab; 2018 Feb; 103(2):397-406. PubMed ID: 29165662
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic value of preoperative systemic inflammatory markers in anaplastic thyroid cancer.
Zhang L; Luo H; Wang L; Liu Y; Rui S; Wu Z; Wei T; Gong R; Li Z; Zhu J
J Surg Oncol; 2020 Oct; 122(5):897-905. PubMed ID: 32596828
[TBL] [Abstract][Full Text] [Related]
29. Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness.
Revilla G; Pons MP; Baila-Rueda L; García-León A; Santos D; Cenarro A; Magalhaes M; Blanco RM; Moral A; Ignacio Pérez J; Sabé G; González C; Fuste V; Lerma E; Faria MDS; de Leiva A; Corcoy R; Carles Escolà-Gil J; Mato E
Sci Rep; 2019 Jul; 9(1):10260. PubMed ID: 31311983
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
Wu H; Sun Y; Ye H; Yang S; Lee SL; de las Morenas A
Pathol Oncol Res; 2015 Jul; 21(3):695-701. PubMed ID: 25588542
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
Carvalho S; Freitas M; Antunes L; Monteiro-Reis S; Vieira-Coimbra M; Tavares A; Paulino S; Videira JF; Jerónimo C; Henrique R
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2127-2137. PubMed ID: 30105513
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
[TBL] [Abstract][Full Text] [Related]
34. HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1.
Pan Z; Fang Q; Li L; Zhang Y; Xu T; Liu Y; Zheng X; Tan Z; Huang P; Ge M
Cancer Lett; 2021 Mar; 501():31-42. PubMed ID: 33359451
[TBL] [Abstract][Full Text] [Related]
35. KAT5 promotes invasion and metastasis through C-MYC stabilization in ATC.
Wei X; Cai S; Boohaker RJ; Fried J; Li Y; Hu L; Pan Y; Cheng R; Zhang S; Tian Y; Gao M; Xu B
Endocr Relat Cancer; 2019 Jan; 26(1):141-151. PubMed ID: 30400007
[TBL] [Abstract][Full Text] [Related]
36. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.
Xu B; David J; Dogan S; Landa I; Katabi N; Saliba M; Khimraj A; Sherman EJ; Tuttle RM; Tallini G; Ganly I; Fagin JA; Ghossein RA
Histopathology; 2022 Jan; 80(2):322-337. PubMed ID: 34449926
[TBL] [Abstract][Full Text] [Related]
37. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
38. IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis.
Haase J; Misiak D; Bauer M; Pazaitis N; Braun J; Pötschke R; Mensch A; Bell JL; Dralle H; Siebolts U; Wickenhauser C; Lorenz K; Hüttelmaier S
Mod Pathol; 2021 Jan; 34(1):32-41. PubMed ID: 32719445
[TBL] [Abstract][Full Text] [Related]
39. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
40. Survival and Prognostic Factors of Anaplastic Thyroid Carcinoma.
Paunovic IR; Sipetic SB; Zoric GV; Diklic AD; Savic DV; Marinkovic J; Zivaljevic VR
Acta Chir Belg; 2015 Jan; 115(1):62-7. PubMed ID: 27384898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
